|
|
| Line 1: |
Line 1: |
| __NOTOC__
| | #REDIRECT [[Verapamil#Package and Label Display Panel]] |
| {{Verapamil}}
| |
| {{CMG}}; {{AE}} {{AK}}
| |
| | |
| ==LABELS AND PACKAGES==
| |
| LAB-0268-7.0
| |
| October 2013
| |
| | |
| PRINCIPAL DISPLAY PANEL - 120 mg Caplet Bottle Label
| |
| | |
| NDC 0025-1901-31
| |
| | |
| 100 Caplets
| |
| Rx only
| |
| | |
| Calan® SR
| |
| (verapamil hydrochloride)
| |
| | |
| SUSTAINED-RELEASE
| |
| | |
| 120 mg
| |
| | |
| Pfizer
| |
| Distributed by
| |
| G.D. Searle LLC
| |
| Division of Pfizer Inc, NY, NY 10017
| |
| | |
| {|
| |
| | |
| | [[image:calansr1.jpg|400px|thumb]]
| |
| | |
| |}
| |
| | |
| PRINCIPAL DISPLAY PANEL - 180 mg Caplet Bottle Label
| |
| | |
| NDC 0025-1911-31
| |
| | |
| 100 Caplets
| |
| Rx only
| |
| | |
| Calan® SR
| |
| (verapamil hydrochloride)
| |
| | |
| SUSTAINED-RELEASE
| |
| | |
| 180 mg
| |
| | |
| Pfizer
| |
| Distributed by
| |
| G.D. Searle LLC
| |
| Division of Pfizer Inc, NY, NY 10017
| |
| | |
| {|
| |
| | |
| | [[image:calansr2.jpg|400px|thumb]]
| |
| | |
| |}
| |
| PRINCIPAL DISPLAY PANEL - 240 mg Caplet Bottle Label
| |
| | |
| NDC 0025-1891-31
| |
| | |
| 100 Caplets
| |
| Rx only
| |
| | |
| Calan® SR
| |
| (verapamil hydrochloride)
| |
| | |
| SUSTAINED-RELEASE
| |
| | |
| 240 mg
| |
| | |
| Pfizer
| |
| Distributed by
| |
| G.D. Searle LLC
| |
| Division of Pfizer Inc, NY, NY 10017
| |
| | |
| {|
| |
| | |
| | [[image:calansr3.jpg|400px|thumb]]
| |
| | |
| |}
| |
| | |
| <ref name="dailymed.nlm.nih.gov">{{Cite web | last = | first = | title = CALAN SR (VERAPAMIL HYDROCHLORIDE) TABLET, FILM COATED, EXTENDED RELEASE [G.D. SEARLE LLC DIVISION OF PFIZER INC] | url = http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=acb6e57b-af44-432f-a4de-a293a2e20121#nlm34090-1 | publisher = | date = | accessdate = }}</ref>
| |
| | |
| | |
| | |
| ==References==
| |
| | |
| {{Reflist|2}}
| |
| | |
| [[Category:Cardiovascular Drugs]]
| |
| [[Category:Drugs]]
| |